Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2020 Available from https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed 324, 2020.
   Google Scholar
• MiravitllesM, SorianoJB, Garcia-RioF, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009;64(10):863–868. doi:10.1136/thx.2009.11572519553233
   PubMed Web of Science ®Google Scholar
• European Respiratory Society. The economic burden of lung disease In: European Lung White Book. 2019.
   Google Scholar
• KhakbanA, SinDD, FitzGeraldJM, et al. The projected epidemic of chronic obstructive pulmonary disease hospitalizations over the next 15 years. a population-based perspective. Am J Respir Crit Care Med. 2017;195(3):287–291. doi:10.1164/rccm.201606-1162PP27626508
   PubMed Web of Science ®Google Scholar
• MerinoM, VilloroR, Hidalgo-VegaA, CarmonaC. Social economic costs of COPD in Extremadura (Spain): an observational study. Int J Chron Obstruct Pulmon Dis. 2018;13:2501–2514. doi:10.2147/COPD.S16735730174420
   PubMed Web of Science ®Google Scholar
• Rutten-van MölkenM, LeeTA. Economic modeling in chronic obstructive pulmonary disease. Annals ATS. 2006;3(7):630–634.
   Google Scholar
• MasaJF, SobradilloV, VillasanteC, et al. Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional. Arch Bronconeumol. 2004;40(2):72–79. doi:10.1016/S0300-2896(04)75476-914746730
   PubMed Web of Science ®Google Scholar
• BlasiF, CesanaG, ContiS, et al. The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS One. 2014;9(6):e101228. doi:10.1371/journal.pone.010122824971791
   PubMed Web of Science ®Google Scholar
• ToyEL, GallagherKF, StanleyEL, SwensenAR, DuhMS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD. 2010;7(3):214–228. doi:10.3109/15412555.2010.48169720486821
   PubMedGoogle Scholar
• PérezM, Puig-PeiróR, AceitunoS, LizánL. Impacto económico de las exacerbaciones agudas en EPOC desde la perspectiva del SNS español. Rev Patol Respir. 2016;19(3):88–95.
   Google Scholar
• de Miguel-diezJ, Jimenez-GarciaR, Hernandez-BarreraV, et al. Trends in hospital admissions for acute exacerbation of COPD in Spain from 2006 to 2010. Respir Med. 2013;107(5):717–723. doi:10.1016/j.rmed.2013.01.00723421969
   PubMed Web of Science ®Google Scholar
• Soler-CatalunaJJ, SauledaJ, ValdesL, et al. Prevalence and perception of 24-h symptom patterns in patients with stable chronic obstructive pulmonary disease in Spain. Arch Bronconeumol. 2016;52(6):308–315. doi:10.1016/j.arbr.2016.03.01926774700
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnacleH, BirkR, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446. doi:10.1164/rccm.201703-0449OC28375647
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnhartF, BrealeyN, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa171390129668352
   PubMed Web of Science ®Google Scholar
• FergusonGT, RabeKF, MartinezFJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, Phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. doi:10.1016/S2213-2600(18)30327-830232048
   PubMed Web of Science ®Google Scholar
• MiravitllesM, Soler-CatalunaJJ, CalleM, et al. Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable. Arch Bronconeumol. 2017;53(6):324–335. doi:10.1016/j.arbres.2017.03.01828477954
   PubMed Web of Science ®Google Scholar
• PhilipsC, ThompsonG What is cost-effectiveness? Hayward Medical Communications. 2009.
   Google Scholar
• ExuzidesA, ColbyC, BriggsAH, et al. Statistical modeling of disease progression for chronic obstructive pulmonary disease using data from the ECLIPSE study. Med Decis Making. 2017;37(4):453–468. doi:10.1177/0272989X1561078126449490
   PubMed Web of Science ®Google Scholar
• BriggsAH, BakerT, RisebroughNA, et al. Development of the galaxy chronic obstructive pulmonary disease (COPD) model using data from ECLIPSE: internal validation of a linked-equations cohort model. Med Decis Making. 2017;37(4):469–480. doi:10.1177/0272989X1665311827317436
   PubMed Web of Science ®Google Scholar
• VestboJ, AndersonW, CoxsonHO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008;31(4):869–873. doi:10.1183/09031936.0011170718216052
   PubMed Web of Science ®Google Scholar
• TabbererM, Gonzalez-McQuireS, MuellerovaH, et al. Development of a conceptual model of disease progression for use in economic modeling of chronic obstructive pulmonary disease. Med Decis Making. 2017;37(4):440–452. doi:10.1177/0272989X1666200927486218
   PubMed Web of Science ®Google Scholar
• RisebroughNA, BriggsA, BakerTM, et al. Validating a model to predict disease progression outcomes in patients with COPD. Value Health. 2014;17(7):A560–561. doi:10.1016/j.jval.2014.08.1852
   PubMed Web of Science ®Google Scholar
• ShahD, DriessenM, RisebroughN, et al. Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. Cost Eff Resour Alloc. 2018;16(1):17. doi:10.1186/s12962-018-0101-329773969
   PubMed Web of Science ®Google Scholar
• HoogendoornM, FeenstraTL, AsukaiY, et al. External validation of health economic decision models for chronic obstructive pulmonary disease (COPD): report of the third COPD modeling meeting. Value Health. 2017;20(3):397–403. doi:10.1016/j.jval.2016.10.01628292484
   PubMed Web of Science ®Google Scholar
• DriessenMT, WhalenJ, Seewoodharry BuguthB, et al. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish national healthcare system perspective. Respir Res. 2018;19(1):224. doi:10.1186/s12931-018-0916-730458866
   PubMed Web of Science ®Google Scholar
• MiravitllesM, GaldizJB, HuertaA, VillacampaA, CarcedoD, Garcia-RioF. Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients. Int J Chron Obstruct Pulmon Dis. 2016;11:123–132. doi:10.2147/COPD.S9400626848262
   PubMed Web of Science ®Google Scholar
• Calle RubioM, CasamorR, MiravitllesM. Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD guidelines: the FENEPOC study. Int J Chron Obstruct Pulmon Dis. 2017;12:2373–2383. doi:10.2147/COPD.S13787228848338
   PubMed Web of Science ®Google Scholar
• Calle RubioM, Alcazar NavarreteB, SorianoJB, et al. Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study. Int J Chron Obstruct Pulmon Dis. 2017;12:417–426. doi:10.2147/COPD.S12448228182155
   PubMed Web of Science ®Google Scholar
• AlmagroP, Martinez-CamblorP, SorianoJB, et al. Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study. PLoS One. 2014;9(2):e89866. doi:10.1371/journal.pone.008986624587085
   PubMed Web of Science ®Google Scholar
• Encuesta de Salud Nacional Espanola. 2011–2012 Available from https://www.mscbs.gob.es/estadEstudios/estadisticas/encuestaNacional/encuesta2011.htm. Accessed 529, 2019.
   Google Scholar
• LeidyNK, WilcoxTK, JonesPW, et al. Development of the exacerbations of chronic obstructive pulmonary disease tool (EXACT): a patient-reported outcome (PRO) measure. Value Health. 2010;13(8):965–975. doi:10.1111/j.1524-4733.2010.00772.x20659270
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline plc. FULFIL Clinical Study Report. 2017.
   Google Scholar
• IQVIA prescribing data for COPD. 2017 Available from: https://www.iqvia.com/. Accessed 529, 2019.
   Google Scholar
• INEbase INdE. 2019 Available from: https://www.ine.es/dyngs/INEbase/en/categoria.htm?c=Estadistica_P&cid=1254735976607. Accessed 529, 2019.
   Google Scholar
• Lopez-BastidaJ, OlivaJ, AntonanzasF, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010;11(5):513–520. doi:10.1007/s10198-010-0244-420405159
   PubMed Web of Science ®Google Scholar
• StarkieHJ, BriggsAH, ChambersMG, JonesP. Predicting EQ-5D values using the SGRQ. Value Health. 2011;14(2):354–360. doi:10.1016/j.jval.2010.09.01121402304
   PubMed Web of Science ®Google Scholar
• VestboJ, LeatherD, Diar BakerlyN, et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med. 2016;375(13):1253–1260. doi:10.1056/NEJMoa160803327593504
   PubMed Web of Science ®Google Scholar
• De CockE, MiravitllesM, González-JuanateyJR, Azanza-PereaJR. Valor umbral del coste por año de vida ganado para recomendar la adopción de tecnologías sanitarias en España: evidencias procedentes de una revisión de la literatura. PharmacoEconomics Spanish Res Art. 2007;4(3):97–107. doi:10.1007/BF3320930
   Google Scholar
• SacristanJA, OlivaJ, Del LlanoJ, PrietoL, PintoJL. What is an efficient health technology in Spain? Gaceta sanitaria. 2002;16(4):334–343. doi:10.1016/s0213-9111(02)71933-x12113733
   PubMedGoogle Scholar
• AtienzaL, BenjaminN, SchroederM, et al. Impact of once-daily single inhaler triple therapy on healthcare resource utilization and associated costs in COPD patients in Spain. Eur Respir J 2018;52(suppl 62):PA3155.
   Google Scholar
• Chiesi Farmaceutici. TRIMBOW Summary of Product Characteristics. 2017.
   Google Scholar
• GlaxoSmithKline plc. Trelegy ELLIPTA Summary of Product Characteristics. 2017.
   Google Scholar
• YuAP, GuerinA, Ponce de LeonD, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ. 2011;14(4):486–496. doi:10.3111/13696998.2011.59412321679019
   PubMedGoogle Scholar
• van der PalenJ, Moeskops-van BeurdenW, DawsonCM, et al. A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:2515–2523. doi:10.2147/COPD.S16906030174421
   PubMed Web of Science ®Google Scholar
• SchroederM, ShahD, RisebroughN, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for patients with advanced chronic obstructive pulmonary disease (COPD) using the FULFIL trial: a UK perspective. Respir Med X. 2019;1(2019):100008.
   Google Scholar
• MartinA, ShahD, SchroederM, et al. P250 Informing the pathway of COPD treatment (the IMPACT study): single inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with COPD – cost-effectiveness in the UK. Thorax. 2018;73(Suppl 4):A237–A237.
   Google Scholar
• AnleyG, ShahD, SchroederM, et al. P249 Informing the pathway of COPD treatment (the IMPACT study): single inhaler triple therapy (FF/UMEC/VI) versus dual bronchodilator therapy (UMEC/VI) in patients with COPD – cost-effectiveness in the UK. Thorax. 2018;73(Suppl 4):A236–A237.
   Google Scholar
• IzquierdoJL, MiravitllesM, EsquinasC, et al. Characteristics of COPD patients managed in respiratory medicine departments in Spain, according to GOLD groups and GesEPOC clinical phenotypes. Archivos de Bronconeumología. 2018;54(11):559–567. doi:10.1016/j.arbr.2018.09.00629853257
   PubMed Web of Science ®Google Scholar
• TashkinDP, CelliB, SennS, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa080580018836213
   PubMed Web of Science ®Google Scholar